{
    "clinical_study": {
        "@rank": "58528", 
        "acronym": "AMASCIS-01", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms."
            }, 
            {
                "arm_group_label": "Allogeneic stem cells from adipose tissue", 
                "arm_group_type": "Experimental", 
                "description": "The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase IIa clinical trial, pilot, single centre, prospective, randomized, double-blind,\n      placebo-controlled, with sequential inclusion of patients"
        }, 
        "brief_title": "Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "20 Patients presenting with a moderate-severe acute ischemic stroke who will be randomized\n      in a 1:1 proportion to intravenous treatment with allogeneic stem cells from adipose tissue\n      or to placebo (vehicle)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Male or female acute ischemic patients aged 60-80 years with symptoms of acute\n             cerebral infarction of less than 12h from stroke onset. If the time of symptom onset\n             is unknown, it shall refer to the last time the patient was asymptomatic seen.\n\n          -  Patients should be treated within two weeks from the onset of stroke symptoms.\n\n          -  Patients with a measurable focal neurological that must persist to the time of\n             treatment without clinically meaningful improvement.\n\n          -  Patients must have computerized tomography (CT) and / or magnetic resonance imaging\n             (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the\n             territory of the middle cerebral artery before being included in the study.\n\n          -  Patients must have a score on the NIH Stroke Scale 8-20, with at least 2 of these\n             points in Sections 5 and 6 (motor deficit) at the time of inclusion.\n\n          -  Immediately (i.e. few minutes) before the stroke, patients should have a score on the\n             mRS \u2264 1 (no symptoms at all or no significant disability despite symptoms, able to\n             perform everyday tasks and activities).\n\n          -  Women of childbearing age should have a negative pregnancy test performed prior to\n             inclusion.\n\n          -  Obtaining informed consent signed (after a detailed explanation of the nature and\n             purpose of this study, the patient or guardian or legal representative must give\n             their consent to participate by signing the informed consent document). Assent from a\n             relative or career if the patient is unable to give meaningful consent (e.g. in cases\n             of dysphasia, confusion, or reduced conscious level).\n\n        Exclusion criteria:\n\n          -  Comatose patients. Patients with a score of 2 or more in the item 1a of the NIHSS\n             related to the degree of awareness.\n\n          -  Evidence on neuroimaging (CT or MRI) of brain tumour, cerebral oedema with midline\n             shift and clinically significant compression of ventricles, cerebellar infarction or\n             brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage.\n\n          -  Current drug or alcohol use or dependence that, in the opinion of the site\n             investigator, would interfere with adherence to study requirements.\u00b7        Active\n             infectious disease, including HIV, hepatitis B, Hepatitis C, etc.\n\n          -  Pre-existing dementia.\n\n          -  Specify health status or any clinical conditions (e.g., life expectancy, co-existing\n             disease) or other characteristics that precludes appropriate diagnosis, treatment or\n             follow-up in the trial.\n\n          -  Patients who are participating in another clinical trial.\n\n          -  Inability or unwillingness of individual or legal guardian/representative to give\n             written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678534", 
            "org_study_id": "AMASCIS-01/2011", 
            "secondary_id": "2011-003551-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "Allogeneic stem cells from adipose tissue", 
                "intervention_name": "Allogenic mesenchymal stem cells from adipose tissue", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cerebral infarction", 
            "Cellular therapy"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "email": "ediez.hulp@salud.madrid.org", 
                "last_name": "Exuperio Diez-Tejedor, MD,PhD", 
                "phone": "0034 917277444"
            }, 
            "contact_backup": {
                "email": "maria.yllescas@idipaz.es", 
                "last_name": "Maria Yllescas, Pharmacist", 
                "phone": "0034 917277558"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }, 
                "name": "University Hospital La Paz"
            }, 
            "investigator": {
                "last_name": "Exuperio Diez-Tejedor, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue. Safety Assessment. A Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial.(AMASCIS-01/2011)", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "La Paz University Hospital Ethic Committe.Country name:Spain", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the safety of treatment with allogeneic stem cells from adipose tissue in acute ischemic stroke patients (Follow-up 24 months):\nAdverse events (AES) reported spontaneously or in response to questions not addressed. Serious adverse events.  These will be recorded in each visit during all the study period (24 months).\nNeurological and systemic complications: deteriorating stroke, stroke recurrences, brain oedema, seizures, hemorrhagic transformation, respiratory infections, urinary tract infections, deep venous thrombosis, pulmonary embolism, gastrointestinal haemorrhage\u2026 These will be recorded in each visit during all the study period (24 months).\nDevelopment of tumours", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678534"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the potential efficacy of allogeneic stem cells from adipose tissue in acute ischemic stroke patients measured by the following parameters:\nOutcome at three months evaluated by: modified Rankin Scale  and the NIH Stroke Scale\ntotal volume of stroke by performing MRI. To identify changes in biochemical markers of brain repair as VEGF, BDNF, MMP-9 and its relationship to neurological and functional outcomes.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "To identify changes in biochemical markers of brain repair as VEGF, BDNF, MMP-9 and its relationship to neurological and functional outcomes.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}